Opinion

Video

Intravesical Novel Therapy for HR BCG-Unresponsive NMIBC

Author(s):

Gary Steinberg, MD, FACS

Gary D. Steinberg, MD, analyzes data from the BOND-003 study presented at AUA 2024, which investigated the use of intravesical cretostimogene grenadenorepvec for treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, and discusses the mechanism of action of this novel oncolytic viral therapy.

Video content above is prompted by the following question(s):

  • Interim data from BOND-003 were just recently presented during the AUA 2024: (A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ).
    • What is the mechanism of action of cretostimogene?
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Related Content
Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC
October 3rd 2024

Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC

Hannah Clarke
In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
September 27th 2024

3D bioprinting technology facilitates development of an in vitro biomimetic bladder model

Kate Gessner, MD, PhD Philip Abbosh, MD, PhD
"This exciting and innovative technology has a wide range of possible applications, including tissue engineering, drug development, and precision medicine," write Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Enfortumab vedotin plus pembrolizumab approved in Japan for urothelial carcinoma
September 24th 2024

Enfortumab vedotin plus pembrolizumab approved in Japan for urothelial carcinoma

Hannah Clarke
Enfortumab vedotin plus pembrolizumab was previously granted a priority review designation from the MHLW.
Plasma ctDNA clearance may be associated with improved outcomes in MIBC
September 23rd 2024

Plasma ctDNA clearance may be associated with improved outcomes in MIBC

Hannah Clarke
According to the authors, these findings from the VOLGA trial suggest that ctDNA may be a potential biomarker to predict therapeutic benefit in patients with MIBC.
© 2024 MJH Life Sciences

All rights reserved.